Drugs / RT01-89Zr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07505069 | Jan → Dec 2026 expected | cancer | Nanolattix Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RT01-89Zr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505069 ↗ |
| Modality | Diagnostic / imaging agent | “radiopharmaceutical diagnostic agent” NCT07505069 ↗ |
| Route | Intravenous | “Intravenous injection of RT01-89Zr” NCT07505069 ↗ |